Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of rituximab, alemtuzumab, and bortezomib on anti-A/anti-B antibody titer kinetics before ABO-incompatible kidney transplantation
NL-OMON39959Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Feb 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of rituximab, alemtuzumab and bortezomib in kidney failure (3 cohorts), sponsored by Leiden University Medical Center. Started Feb 2013; status: active, not recruiting.
02
Drugs
rituximabalemtuzumabbortezomib
03
Conditions
kidney failure
Beyond the preview
Go deeper on NL-OMON39959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39959.